NCT00521053View on ClinicalTrials.gov

Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

May 31, 2010

Study Completion Date

June 30, 2012

Conditions
Melanoma
Interventions
DRUG

PV-10 (10% rose bengal disodium)

Intralesional injection for chemoablation

Trial Locations (7)

2050

Sydney Melanoma Unit, Sydney

4102

Princess Alexandra Hospital, Woolloongabba

5000

Royal Adelaide Hospital, Adelaide

18015

St Luke's Hospital & Health Network, Bethlehem

40202

University of Louisville, Louisville

77030

M.D. Anderson Cancer Center, Houston

94115

California Pacific Medical Center, San Francisco

Sponsors
All Listed Sponsors
lead

Provectus Pharmaceuticals

INDUSTRY